ERBB2 and neoplasm: As shown in Fig. 1A, administration of anti-neu mAb to spontaneous mammary tumours bearing BALB/c-NeuT mice resulted in significant delay in tumour outgrowth (p < 0.001), leading to significant improvement in survival when compared with untreated mice (Fig. 1B) (p < 0.01).